BofA Securities analyst Alec Stranahan initiates coverage on $Intellia Therapeutics (NTLA.US)$ with a buy rating, and sets the target price at $65.
According to TipRanks data, the analyst has a success rate of 50.5% and a total average return of -2.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
Following the presentation of Phase 2 data for NTLA-2002, which indicated a reduction in attack rates that was perceived as less notable compared to earlier Phase 1 results for HAE, expectations for the treatment's market share peak have been moderated. Despite this, the unique 'one-and-done' administration of NTLA-2002 remains a key differentiator from other treatments requiring more frequent dosing. The market opportunity for NTLA-2002 continues to be seen as competitive, but anticipations have been tempered due to revised success probabilities for NTLA-2001 in ATTR, pending further validation of the platform.
The perspective on Intellia Therapeutics has become incrementally negative after evaluating the Phase 2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
